Search Results - subject:"reference pricing"

Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania

Lopert, Ruth; Ruiz, Francis; Chalkidou, Kalipso - In: Health Policy 112 (2013) 3, pp. 202-208

In attempting to constrain healthcare expenditure growth, health technology assessment (HTA) can enable policy-makers to look beyond budget impact and facilitate more rational decision-making. However lack of technical capacity and poor governance can limit use in some countries. Undertaking de...

Persistent link: https://www.econbiz.de/10010719287

Should pharmaceutical costs be curbed?

Brekke, Kurt R.; Dalen, Dag Morten; Strøm, Steinar - In: Nordic economic policy review (2012) 2, pp. 247-273

Persistent link: https://www.econbiz.de/10010379568

The impact of generic reference pricing interventions in the statin market

Puig, Jaume - Department of Economics and Business, Universitat … - 2005

public financing reforms applied to the prescription of statins: a Spanish generic reference pricing (RP) system for …

Persistent link: https://www.econbiz.de/10005771923

The impact of generic reference pricing interventions in the statin market

Puig, Jaume - Department of Economics and Business, Universitat … - 2005

public financing reforms applied to the prescription of statins: a Spanish generic reference pricing (RP) system for …

Persistent link: https://www.econbiz.de/10005772053

Reference Pricing of Pharmaceuticals

Brekke, Kurt R; Königbauer, Ingrid; Straume, Odd Rune - Institutt for Økonomi, Universitetet i Bergen - 2005

reference pricing (GRP), therapeutic reference pricing (TRP), and no reference pricing (NRP). We show that competition is …

Persistent link: https://www.econbiz.de/10008918559

Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data

Vrijens, France; Voorde, Carine Van de; Farfan-Portet, … - In: The European Journal of Health Economics 13 (2012) 3, pp. 315-325

Persistent link: https://www.econbiz.de/10010557842

Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data

Farfan-Portet, Maria-Isabel; Voorde, Carine Van de; … - In: The European Journal of Health Economics 13 (2012) 3, pp. 301-313

Persistent link: https://www.econbiz.de/10010557845

The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs

Grootendorst, Paul V.; Marshall, John K.; Holbrook, Anne M. - Department of Economics, McMaster University - 2004

, generic substitution (GS) and reference pricing (RP), in April 1994 and November 1995, respectively, to the NSAIDs. Under GS …

Persistent link: https://www.econbiz.de/10005404447

Regulatory ambivalence and the limitations of pharmaceutical policy in Spain

Costa, Joan; Puig, Jaume - Department of Economics and Business, Universitat … - 2004

Broadly speaking, pharmaceutical policy in Spain has been unable to control either the price or the volume of drugs prescribed. Limited attempts have been made to bring together the regulation of the pharmaceutical market and policies, in pursuit of the desired goals of efficiency and quality....

Persistent link: https://www.econbiz.de/10005707999

Regulatory ambivalence and the limitations of pharmaceutical policy in Spain

Costa, Joan; Puig, Jaume - Department of Economics and Business, Universitat … - 2004

Persistent link: https://www.econbiz.de/10005704844